相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。501OCALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH EXPANDED RAS ANALYSES UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (MCRC)
H. Lenz et al.
ANNALS OF ONCOLOGY (2017)
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PANITUMUMAB PLUS FOLFOX4 OR PANITUMUMAB PLUS FOLFIRI IN SUBJECTS WITH WILD-TYPE KRAS (EXON 2) COLORECTAL CANCER AND MULTIPLE OR UNRESECTABLE LIVER-LIMITED METASTASES: DATA FROM THE RANDOMIZED, PHASE II PLANET STUDY
A. Abad et al.
ANNALS OF ONCOLOGY (2014)
KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB plus FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS
M. Peeters et al.
ANNALS OF ONCOLOGY (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience
Joanne W. Chiu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Tolerability study of adjuvant modified FOLFOX6 treatment in curatively resected stage II/III colon cancer (JFMC41-1001-C2: JOIN trial).
Katsunori Shinozaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Lee S. Schwartzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
Matthew T. Seymour et al.
LANCET ONCOLOGY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Arjun Sood et al.
CLINICAL COLORECTAL CANCER (2012)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
Kjell Magne Tveit et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
Timothy S. Maughan et al.
LANCET (2011)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
J. H. J. M. van Krieken et al.
VIRCHOWS ARCHIV (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
分享论文
